Research·October 13, 2026 at 10:59 AM EDT·2 sources
BioNTech’s head and neck cancer vaccine misses first of two goals
BNTX -1.7%
BNTX · last 30 trading days-8.1% since the news
News
What happened
- BioNTech’s experimental mRNA cancer vaccine failed to meet one of two primary endpoints in a pivotal trial.
- An early data check found the treatment did not delay tumor progression in a form of head and neck cancer.
- BioNTech said the therapy could still potentially extend survival, according to BioPharma Dive.
Primary endpoints missed
one of two
Why it matters
The result adds pressure to BioNTech’s cancer-treatment pipeline and may affect expectations for its mRNA oncology programs. Healthcare investors and research professionals will focus on whether the therapy can show a survival benefit despite the progression result.
What to watch. Further survival data from the study, if reported.
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
Timeline
- First reported by Endpoints NewsOct 13BioNTech’s head and neck cancer vaccine misses first of two goals
- BioPharma Dive reportsOct 13BioNTech mRNA cancer immunotherapy misses first objective in key study
Sources (2)
- Endpoints NewsOct 13BioNTech’s head and neck cancer vaccine misses first of two goals
- BioPharma DiveOct 13BioNTech mRNA cancer immunotherapy misses first objective in key study
Related
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
- Why it matters to youEvery story matched to your watchlist, your contacts and your pipeline.
- Follow developing storiesAn alert, and a push, the moment a story you follow moves.
- Your briefing, read aloudA few minutes each morning with a chapter per story.
- Brief modeSwipe through the day, a 20-second card each.